This is the company's third international buyout in the last 12 months. Last year in October, the company had acquired Pinewood, the largest generic firm in Ireland and the biggest supplier of liquid generic products in the UK. Wockhardt had also bought Negma, the fourth largest independent pharmaceutical firm in France in May.
Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday announced a shift in its United States (US) operations. The Indian pharma giant revealed that it has decided to exit the generics pharmaceutical segment in the country.
The FDA had imposed a ban on the company's Waluj plant in May.
Wockhardt MD Murtaza Khorakiwala said his firm had responded to the FDA's observations but declined to give details.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances